Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam, Dharmacon, CytRx

Premium

Alnylam Licenses Kreutzer-Limmer IP to Dharmacon

Alnylam Pharmaceuticals said this week that it has granted Dharmacon a non-exclusive license to provide RNAi research products and services under the Kreutzer-Limmer patent family.

Specific terms of the deal were not disclosed.

The European patent family, acquired by Alnylam through its merger with Ribopharma in July 2003, covers the use of siRNAs to mediate RNAi in mammalian cells. A key patent in the family, EP 1144623/WO 0044895, is currently being opposed by five companies: Sirna Therapeutics, Atugen, Aventis Pharma, Janssen Pharmaceutica, and AstraZeneca.

Isis Pharmaceuticals and Novartis had also been opposing the patent, but dropped their opposition after establishing partnerships with Alnylam.


CytRx Shares Regain Nasdaq Listing Compliance

CytRx said this week that it has regained full compliance for continued listing on the Nasdaq Capital Market by satisfying the $1 minimum bid price requirement for 10 consecutive market trading days.

According to the company, it was first notified on June 7 last year that its shares failed to meet the bid requirement and faced delisting. CytRx had until June 2 to regain compliance with the Nasdaq's $1 minimum bid price requirement.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.